James Campbell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/840648/publications.pdf

Version: 2024-02-01

31 papers	3,023 citations	304743 22 h-index	434195 31 g-index
36 all docs	36 docs citations	36 times ranked	6299 citing authors

#	Article	IF	Citations
1	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353
2	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nature Communications, 2018, 9, 1849.	12.8	310
3	Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity. Cancer Research, 2014, 74, 287-297.	0.9	290
4	Secondary mutations in <scp>BRCA2</scp> associated with clinical resistance to a <scp>PARP</scp> inhibitor. Journal of Pathology, 2013, 229, 422-429.	4.5	287
5	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nature Communications, 2016, 7, 13837.	12.8	272
6	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 2016, 6, 838-851.	9.4	222
7	A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity. PLoS ONE, 2013, 8, e61520.	2.5	147
8	Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research, 2013, 19, 5485-5493.	7.0	126
9	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS ONE, 2011, 6, e28527.	2.5	106
10	Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer. Cancer Discovery, 2013, 3, 1058-1071.	9.4	103
11	Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Reports, 2016, 14, 2490-2501.	6.4	97
12	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British Journal of Cancer, 2017, 117, 113-123.	6.4	84
13	Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Molecular Cancer Therapeutics, 2016, 15, 1472-1484.	4.1	73
14	Plasma Gelsolin is Decreased and Correlates with Rate of Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 585-596.	2.6	69
15	Proteome-Based Plasma Markers of Brain Amyloid-Î² Deposition in Non-Demented Older Individuals. Journal of Alzheimer's Disease, 2011, 22, 1099-1109.	2.6	69
16	Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Molecular Cancer Therapeutics, 2017, 16, 2022-2034.	4.1	66
17	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE, 2016, 11, e0149099.	2.5	60
18	ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Research, 2017, 77, 7014-7026.	0.9	43

#	Article	IF	Citations
19	Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics, 2011, 11, 1148-1152.	2.2	34
20	Pervasive and opposing effects of Unpredictable Chronic Mild Stress (UCMS) on hippocampal gene expression in BALB/cJ and C57BL/6J mouse strains. BMC Genomics, 2015, 16, 262.	2.8	30
21	Candidate verification of iron-regulated Neisseria meningitidis proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring. Journal of Proteomics, 2009, 73, 231-239.	2.4	27
22	Comparison of a Protein-Level and Peptide-Level Labeling Strategy for Quantitative Proteomics of Synaptosomes Using Isobaric Tags. Journal of Proteome Research, 2010, 9, 2725-2733.	3.7	26
23	Increased platelet expression of glycoprotein <scp>IIIa</scp> following aspirin treatment in aspirinâ€resistant but not aspirinâ€sensitive subjects. British Journal of Clinical Pharmacology, 2014, 78, 320-328.	2.4	24
24	Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nature Communications, 2018, 9, 2016.	12.8	22
25	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut, 2018, 67, 1780-1792.	12.1	19
26	Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics, 2012, 12, 2355-2365.	2.2	18
27	Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. Scientific Data, 2017, 4, 170020.	5.3	14
28	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports, 2018, 8, 10614.	3.3	13
29	A novel strategy using MASCOT Distiller for analysis of cleavable isotope-coded affinity tag data to quantify protein changes in plasma. Proteomics, 2005, 5, 3040-3044.	2.2	9
30	CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. Cell Systems, 2017, 5, 82-86.e3.	6.2	5
31	Proteomics for Brain Disordersâ€"The Promise for Biomarkers. Annals of the New York Academy of Sciences, 2009, 1180, 68-74.	3.8	4